Aug 5, 2026 earnings call — Acquired cliramitug royalty, raised 2026 outlook
Raised 2026 portfolio receipts guidance to $3.4 billion to $3.5 billion.
Revenue $0.8B (est $0.8B) · EPS $1.32 (est $1.27) · Next-quarter revenue outlook $3.4B–$3.5B
Key quotes
"Beginning on Slide 9, we recently acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million."
"At that time, we had 3 potential therapies in the pipeline. Today, we have 19, a more than sixfold increase."
"Under our value-driven capital allocation framework, we also returned around $370 million to shareholders in dividends and share repurchases in the first half of the year."
Analyst Q&A 8
deal terms and interest rates
Q (Geoffrey Meacham · Citi): Analyst asked if Royalty can use more equity in deals and whether lower rates or a better credit rating would make them put more capital to work.
A: They said they have a lot of financial flexibility and can partner in different ways on M&A deals. They also said they are agnostic to the rate environment and will continue to access debt markets while keeping an investment grade rating.
"As far as rates, I think that the way that we view rates is we truly are agnostic to the rate environment." — Terrance Coyne (CFO)
Amvuttra outlook and synthetic royalties
Q (Terence Flynn · Morgan Stanley): Analyst asked how the CARDIO-TTRansform results affect Amvuttra and for an update on the synthetic royalty market and board openness.
A: They said Amvuttra is well positioned and could benefit if Alnylam's follow-on is delayed or faces changes. They also said they remain very excited about the synthetic royalty market and cited strong recent deal activity and growth.
"Last year, we announced synthetics for just over $2 billion, including the RevMed deal, which was really one of the largest synthetics ever." — Christopher Hite (CHAIR)
approved vs development mix; China
Q (Christopher Schott · JPM): Analyst asked if Royalty wants to shift more into development-stage assets and for any early learnings from China expansion.
A: They said the 65% approved / 35% unapproved split has been consistent and they expect it to stay similar over a rolling 2–3 year view, though unapproved could rise toward the mid- to high-teens of invested capital. They said China is early days, they have hired a top local player, are engaging more, and will be patient while building that market.
"So regarding the split between unapproved and approved, I think that ratio of 65%, 35% has been sort of consistent over the last 5, 10 years." — Pablo Legorreta (CEO·CHAIR)
moat versus rivals and expenses
Q (Michael Nedelcovych · TD Cowen): First, analyst asked why Q2 operating costs were relatively low and why costs may rise in H2. Second, asked why a competitor could not replicate Royalty Pharma.
A: They said Royalty has large barriers: scale, low cost of capital, a deep team, and a unique, long-built portfolio that produces recurring revenue and is hard to reproduce. On operating costs they said internalization synergies are realized and there is seasonality, with second-half cash-based costs tending to be a bit higher than the first half.
"It's a portfolio that produces $3.2 billion last year of recurring revenue, predictable recurring revenue from a very well-diversified portfolio of products and its top products marketed by top companies." — Pablo Legorreta (CEO·CHAIR)
returns by stage and pelacarsen
Q (Ashwani Verma · UBS): Analyst asked what IRR they target for development-stage versus approved products and what MACE reduction would be clinically meaningful for pelacarsen.
A: They said unlevered IRR expectations for approved products are in the high single to low double-digit range and unapproved assets are expected to be in the teens. On pelacarsen they said Novartis has been explicit on clinical relevance and they are eagerly awaiting the outcome study results to learn more.
"So what we've communicated is that for approved products, or on-market products, our unlevered IRR expectations are in the high single to low double-digit range." — Marshall Urist
cliramitug trial and R&D funding
Q (Michael DiFiore · Evercore): Analyst asked how they handicap the Phase III cardiovascular trial for cliramitug given Phase I biomarker data and about avoiding adverse selection when co-funding R&D.
A: They said cliramitug has intriguing biomarker and imaging data showing amyloid removal and noted TTR amyloidosis programs traditionally go to Phase III on biomarker data. On co-funding they said they set a very high bar, actively push to fund the most exciting assets, and are disciplined, citing recent Teva and J&J transactions as examples.
"TTR amyloidosis is a disease where every product has gone into a Phase III outcome study based on biomarker data." — Marshall Urist
tracking to 2030 goal and new areas
Q (Asad Haider · Goldman Sachs): Analyst asked how they are tracking to the $4.7 billion portfolio receipts goal by 2030 and what new therapeutic areas are attracting interest.
A: They said they feel very good about tracking to the $4.7 billion-plus 2030 guidance and it's early to change that view. They said they remain open to great products in any therapeutic area and will analyze broadly rather than pick specific new areas now.
"So on our long-term guidance of $4.7 billion or more on the top line by 2030, we feel really good about where we're tracking." — Terrance Coyne (CFO)
China policy risk and milestones
Q (Jason Gerberry · BofA): Analyst asked if U.S. policy risks or proposed license restrictions change their China approach and whether milestones could be larger in H2 with upcoming PDUFAs.
A: They said China is an attractive innovation source and many Chinese companies out-license to U.S./European partners under offshore entities, creating royalties under U.S./European law, and they are monitoring proposed U.S. legislation but remain committed with local hires. They reiterated they expect milestones and other contractual receipts to be around $60 million for the year.
"And then, Jason, your question on milestones, just to sort of reiterate what we said previously, we continue to expect milestones and other contractual receipts to be around $60 million for the year." — Terrance Coyne (CFO)